RIVER EDGE, NJ, May 23 , 2016 /Issuer Direct / — Nephros, Inc. (OTCQB:NEPH), (the “Company”) a commercial stage medical device company that develops and sells high performance liquid purification ultrafilters, announced today that it has signed a distribution agreement with CS Medical, LLC, a leader in developing, manufacturing, and marketing medical devices designed to provide high-level disinfection of ultrasound Trans-Esophageal Echocardiogram (“TEE”) probes.
CS Medical’s TD 100® Automated TEE Probe Disinfector is designed to provide high-level disinfection for delicate TEE probes, thus minimizing the potential of patient exposure to improperly reprocessed TEE ultrasound probes. Nephros ultrafilters will provide an additional level of reassurance by delivering high quality rinse water, after high-level disinfection, that is free of potentially harmful waterborne bacteria, viruses and endotoxins.
“By offering the Nephros ultrafilters to our TD 100 customers, CS Medical is once again proving its commitment to innovation and continued focus on the reduction of healthcare associated infections,” said Mark Leath, President of CS Medical.
“We are very excited about our partnership with CS Medical and our opportunity to help protect patients undergoing a TOE or TEE procedure,” said Shane Sullivan, Nephros Director of North American Sales. “Our FDA cleared ultrafilters are able to meet the water purity needs of a number of specialized medical devices, including CS Medical’s market leading device, the TD 100.”
About CS Medical:
Founded in 2003, CS Medical LLC is the leader in developing, manufacturing, and marketing medical devices that are designed to provide high-level disinfection of ultrasound TEE probes.
CS Medical’s products are engineered and developed with one single objective in mind: to minimize the potential of patient exposure to improperly reprocessed TEE ultrasound probes. Our core product, the TD 100, is an example of our ongoing commitment to innovation and to the health and safety of medical patients and staff. The TD 100 Automated TEE Probe Disinfector eliminates manual reprocessing of delicate and expensive TEE ultrasound probes while providing a repeatable and FDA cleared disinfection process. With over 2 million successful high-level disinfections to date, the TD 100 is the standard for automated reprocessing of TEE and TOE probes in North America.
Located in Creedmoor, North Carolina, CS Medical’s products provide quality device care and storage by minimizing healthcare operational costs, improving device readiness and increasing regulatory compliance. For more information about CS Medical, please visit the company’s website at www.csmedicalllc.com
About Nephros, Inc.
Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters, as well as a hemodiafiltration system for the treatment of patients with End Stage Renal Disease. Its filters, which it calls ultrafilters, are used primarily in medical applications. Nephros ultrafilters are used by dialysis centers for the removal of biological contaminants from the water and bicarbonate concentrate feeding hemodialysis devices. Additionally, Nephros ultrafilters are used in hospitals and medical clinics as an aid in infection control by retaining bacteria (i.e. Legionella, Pseudomonas), virus and endotoxin from water used by patients.
For more information about Nephros, please visit the company’s website at www.nephros.com.
This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the potential benefits of a distribution agreement between CS Medical, LLC and Nephros, Inc., and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including potential delays in the regulatory approval process, changes in business, economic and competitive conditions, the availability of capital when needed, our dependence on third party manufacturers, regulatory reforms, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Nephros Inc.’s reports filed with the U.S. Securities and Exchange Commission, including with respect to Nephros, its Annual Report on Form 10-K for the year ended December 31, 2015. Nephros, Inc. does not undertake any responsibility to update the forward-looking statements in this release.